Ads
related to: novartis
Search results
Novartis leukemia drug more effective than older treatments in trial
AOL· 54 minutes agoSwiss drugmaker Novartis said patients with a type of leukemia who took its Scemblix had a significantly better response and a lower dropout rate than those who received current ...
Novartis study points to larger role for targeted leukemia drug
BioPharma Dive via Yahoo Finance· 5 hours agoResults from a trial called ASC4FIRST show Scemblix outperformed Gleevec and other kinase inhibitors...
Novartis reports Phase III data for trials of remibrutinib to treat CSU
Clinical Trials Arena via Yahoo Finance· 2 hours agoNovartis has released new data from two Phase III clinical trials confirming the sustained efficacy...
US pharma giant Cencora says Americans' health information stolen in data breach
TechCrunch· 7 days agoU.S. pharmaceutical giant Cencora says it is notifying affected individuals that their personal and...
Novartis stock rated 'Buy' by Goldman Sachs, highlighting robust innovation By Investing.com
Investing.com· 1 day agoOn Thursday, Goldman Sachs (NYSE:GS) initiated coverage on Novartis AG (SIX:NOVN) stock, listed as...
Pharmaceutical Giant Cencora Confirms Patient Data Breach Impacting over a Dozen Pharma Companies -...
CPO Magazine· 2 hours agoU.S. pharmaceutical giant Cencora has disclosed that the February 2024 data breach leaked sensitive...
Novartis sues Maryland over law mandating discounts for hospitals' outside pharmacies
Reuters· 19 hours agoLike other...
Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further...
WLNS Lansing· 6 days ago...atrasentan is a potent, selective ETA receptor antagonist with potential to reduce persistent...
Novartis (NVS) Presents Positive Data on Renal Drugs at ERA
Zacks· 4 days agoNovartis (NVS) presents data on Fabhalta in adult patients with C3 glomerulopathy and atrasentan in...
Novartis to seek approvals in two rare kidney diseases after positive Phase 3 trials
Endpoints News· 6 days agoNovartis is building out its rare kidney disease portfolio with two batches of Phase 3 data at the...